Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design At ASPC Congress 2024; Topline Data Is Expected First Half Of 2025

Author: Benzinga Newsdesk | August 02, 2024 04:31pm

• Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP —
• Dosing regimens are informed by six previous Phase 1 and Phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as PK/PD modeling —
• Topline data is expected first half of 2025 —
• Data from Phase 2 TRANQUILITY trial have the potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases.

NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today presented a poster at the American Society of Preventive Cardiology (ASPC) Congress in Salt Lake City, Utah, detailing the rationale and design of the company's TRANQUILITY Phase 2 study examining the potential of its lead candidate, TOUR006, to reduce high-sensitivity C-reactive protein (hs-CRP), a key biomarker of residual inflammatory cardiovascular risk, in patients with chronic kidney disease (CKD) and elevated hs-CRP.

Patients with CKD and elevated hs-CRP are at heightened risk of atherosclerotic cardiovascular disease (ASCVD), including heart attack, stroke, and peripheral artery disease, despite current standard-of-care treatments. The IL-6 pathway has been identified as a significant contributor to ASCVD risk, particularly in CKD patients. TOUR006 has previously shown promise in reducing hs-CRP levels in patients with inflammatory autoimmune diseases.

Posted In: TRML